Companies partner to develop biologics-based lower back pain treatment

Written by Eric Oliver | September 10, 2019 | Print  |

Drugmakers Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.

The companies are developing and commercializing MPC-06-ID, a phase 3 allogeneic cell therapy candidate. The companies hope the therapy can treat chronic lower back pain caused by degenerative disc disease. If successful, Grünenthal will have commercialization rights to the drug in Europe and Latin America.

More articles on biologics:
Stryker adds to spine division with $550M acquisition: 3 details
New York spine surgeon pleads guilty to illegal painkiller prescription, faces $250K fine
15 spine, neurosurgeon moves in August

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months